Propanc Biopharma, Inc.
PPCB
$1.87
-$0.08-4.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -12,467.95% | -21.42% | 1.20% | 31.92% | 9.87% |
| Total Depreciation and Amortization | 18.60% | -21.82% | -5.17% | 20.83% | -18.64% |
| Total Amortization of Deferred Charges | -22.29% | 34.56% | 20.25% | -41.98% | -14.36% |
| Total Other Non-Cash Items | 49,875.42% | 945.67% | -108.49% | 24,833.33% | -99.62% |
| Change in Net Operating Assets | -18.13% | 241.80% | 166.12% | -130.93% | 283.71% |
| Cash from Operations | -2,061.90% | 97.32% | 9.42% | -152.92% | 56.97% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 9.71% | -17.39% | -9.75% | 329.86% | -79.70% |
| Total Debt Repaid | 91.87% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 8.11% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 134.96% | -63.00% | -14.06% | 276.88% | -75.68% |
| Foreign Exchange rate Adjustments | 77.71% | -952.50% | -66.53% | 181.57% | -197.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 568.52% | 145.76% | -179.19% | 122.78% | -200.62% |